MRC5 cells engineered to express ACE2 serve as a model system for the discovery of antivirals targeting SARS-CoV-2
Although the spread of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has resulted in a worldwide pandemic, there are currently no virus-specific drugs that are fully effective against SARS-CoV-2. Only a limited number of human-derived cells are capable of supporting SARS-CoV-2 replica...
Saved in:
Published in | Scientific reports Vol. 11; no. 1; pp. 5376 - 9 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
08.03.2021
Nature Publishing Group Nature Portfolio |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Although the spread of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has resulted in a worldwide pandemic, there are currently no virus-specific drugs that are fully effective against SARS-CoV-2. Only a limited number of human-derived cells are capable of supporting SARS-CoV-2 replication and the infectivity of SARS-CoV-2 in these cells remains poor. In contrast, monkey-derived Vero cells are highly susceptibility to infection with SARS-CoV-2, although they are not suitable for the study of antiviral effects by small molecules due to their limited capacity to metabolize drugs compared to human-derived cells. In this study, our goal was to generate a virus-susceptible human cell line that would be useful for the identification and testing of candidate drugs. Towards this end, we stably transfected human lung-derived MRC5 cells with a lentiviral vector encoding angiotensin-converting enzyme 2 (ACE2), the cellular receptor for SARS-CoV-2. Our results revealed that SARS-CoV-2 replicates efficiently in MRC5/ACE2 cells. Furthermore, viral RNA replication and progeny virus production were significantly reduced in response to administration of the replication inhibitor, remdesivir, in MRC5/ACE2 cells compared with Vero cells. We conclude that the MRC5/ACE2 cells will be important in developing specific anti-viral therapeutics and will assist in vaccine development to combat SARS-CoV-2 infections. |
---|---|
AbstractList | Although the spread of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has resulted in a worldwide pandemic, there are currently no virus-specific drugs that are fully effective against SARS-CoV-2. Only a limited number of human-derived cells are capable of supporting SARS-CoV-2 replication and the infectivity of SARS-CoV-2 in these cells remains poor. In contrast, monkey-derived Vero cells are highly susceptibility to infection with SARS-CoV-2, although they are not suitable for the study of antiviral effects by small molecules due to their limited capacity to metabolize drugs compared to human-derived cells. In this study, our goal was to generate a virus-susceptible human cell line that would be useful for the identification and testing of candidate drugs. Towards this end, we stably transfected human lung-derived MRC5 cells with a lentiviral vector encoding angiotensin-converting enzyme 2 (ACE2), the cellular receptor for SARS-CoV-2. Our results revealed that SARS-CoV-2 replicates efficiently in MRC5/ACE2 cells. Furthermore, viral RNA replication and progeny virus production were significantly reduced in response to administration of the replication inhibitor, remdesivir, in MRC5/ACE2 cells compared with Vero cells. We conclude that the MRC5/ACE2 cells will be important in developing specific anti-viral therapeutics and will assist in vaccine development to combat SARS-CoV-2 infections. Although the spread of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has resulted in a worldwide pandemic, there are currently no virus-specific drugs that are fully effective against SARS-CoV-2. Only a limited number of human-derived cells are capable of supporting SARS-CoV-2 replication and the infectivity of SARS-CoV-2 in these cells remains poor. In contrast, monkey-derived Vero cells are highly susceptibility to infection with SARS-CoV-2, although they are not suitable for the study of antiviral effects by small molecules due to their limited capacity to metabolize drugs compared to human-derived cells. In this study, our goal was to generate a virus-susceptible human cell line that would be useful for the identification and testing of candidate drugs. Towards this end, we stably transfected human lung-derived MRC5 cells with a lentiviral vector encoding angiotensin-converting enzyme 2 (ACE2), the cellular receptor for SARS-CoV-2. Our results revealed that SARS-CoV-2 replicates efficiently in MRC5/ACE2 cells. Furthermore, viral RNA replication and progeny virus production were significantly reduced in response to administration of the replication inhibitor, remdesivir, in MRC5/ACE2 cells compared with Vero cells. We conclude that the MRC5/ACE2 cells will be important in developing specific anti-viral therapeutics and will assist in vaccine development to combat SARS-CoV-2 infections.Although the spread of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has resulted in a worldwide pandemic, there are currently no virus-specific drugs that are fully effective against SARS-CoV-2. Only a limited number of human-derived cells are capable of supporting SARS-CoV-2 replication and the infectivity of SARS-CoV-2 in these cells remains poor. In contrast, monkey-derived Vero cells are highly susceptibility to infection with SARS-CoV-2, although they are not suitable for the study of antiviral effects by small molecules due to their limited capacity to metabolize drugs compared to human-derived cells. In this study, our goal was to generate a virus-susceptible human cell line that would be useful for the identification and testing of candidate drugs. Towards this end, we stably transfected human lung-derived MRC5 cells with a lentiviral vector encoding angiotensin-converting enzyme 2 (ACE2), the cellular receptor for SARS-CoV-2. Our results revealed that SARS-CoV-2 replicates efficiently in MRC5/ACE2 cells. Furthermore, viral RNA replication and progeny virus production were significantly reduced in response to administration of the replication inhibitor, remdesivir, in MRC5/ACE2 cells compared with Vero cells. We conclude that the MRC5/ACE2 cells will be important in developing specific anti-viral therapeutics and will assist in vaccine development to combat SARS-CoV-2 infections. Abstract Although the spread of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has resulted in a worldwide pandemic, there are currently no virus-specific drugs that are fully effective against SARS-CoV-2. Only a limited number of human-derived cells are capable of supporting SARS-CoV-2 replication and the infectivity of SARS-CoV-2 in these cells remains poor. In contrast, monkey-derived Vero cells are highly susceptibility to infection with SARS-CoV-2, although they are not suitable for the study of antiviral effects by small molecules due to their limited capacity to metabolize drugs compared to human-derived cells. In this study, our goal was to generate a virus-susceptible human cell line that would be useful for the identification and testing of candidate drugs. Towards this end, we stably transfected human lung-derived MRC5 cells with a lentiviral vector encoding angiotensin-converting enzyme 2 (ACE2), the cellular receptor for SARS-CoV-2. Our results revealed that SARS-CoV-2 replicates efficiently in MRC5/ACE2 cells. Furthermore, viral RNA replication and progeny virus production were significantly reduced in response to administration of the replication inhibitor, remdesivir, in MRC5/ACE2 cells compared with Vero cells. We conclude that the MRC5/ACE2 cells will be important in developing specific anti-viral therapeutics and will assist in vaccine development to combat SARS-CoV-2 infections. |
ArticleNumber | 5376 |
Author | Toba, Shinsuke Takahashi, Yoshimasa Sato, Akihiko Orba, Yasuko Uemura, Kentaro Sanaki, Takao Maenaka, Katsumi Sawa, Hirofumi Hall, William W. Sasaki, Michihito |
Author_xml | – sequence: 1 givenname: Kentaro surname: Uemura fullname: Uemura, Kentaro organization: Drug Discovery and Disease Research Laboratory, Shionogi & Co., Ltd, Division of Molecular Pathobiology, Research Center for Zoonosis Control, Hokkaido University, Laboratory of Biomolecular Science, Faculty of Pharmaceutical Sciences, Hokkaido University – sequence: 2 givenname: Michihito surname: Sasaki fullname: Sasaki, Michihito organization: Division of Molecular Pathobiology, Research Center for Zoonosis Control, Hokkaido University – sequence: 3 givenname: Takao surname: Sanaki fullname: Sanaki, Takao organization: Drug Discovery and Disease Research Laboratory, Shionogi & Co., Ltd, Division of Molecular Pathobiology, Research Center for Zoonosis Control, Hokkaido University – sequence: 4 givenname: Shinsuke surname: Toba fullname: Toba, Shinsuke organization: Drug Discovery and Disease Research Laboratory, Shionogi & Co., Ltd, Division of Molecular Pathobiology, Research Center for Zoonosis Control, Hokkaido University – sequence: 5 givenname: Yoshimasa surname: Takahashi fullname: Takahashi, Yoshimasa organization: Department of Immunology, National Institute of Infectious Diseases – sequence: 6 givenname: Yasuko surname: Orba fullname: Orba, Yasuko organization: Division of Molecular Pathobiology, Research Center for Zoonosis Control, Hokkaido University, International Collaboration Unit, Research Center for Zoonosis Control, Hokkaido University – sequence: 7 givenname: William W. surname: Hall fullname: Hall, William W. organization: International Collaboration Unit, Research Center for Zoonosis Control, Hokkaido University, National Virus Reference Laboratory, School of Medicine, University College of Dublin, Global Virus Network – sequence: 8 givenname: Katsumi surname: Maenaka fullname: Maenaka, Katsumi organization: Laboratory of Biomolecular Science, Faculty of Pharmaceutical Sciences, Hokkaido University, Center for Research and Education On Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Global Station for Biosurfaces and Drug Discovery, Hokkaido University – sequence: 9 givenname: Hirofumi surname: Sawa fullname: Sawa, Hirofumi organization: Division of Molecular Pathobiology, Research Center for Zoonosis Control, Hokkaido University, International Collaboration Unit, Research Center for Zoonosis Control, Hokkaido University, Global Virus Network – sequence: 10 givenname: Akihiko surname: Sato fullname: Sato, Akihiko email: akihiko.sato@shionogi.co.jp organization: Drug Discovery and Disease Research Laboratory, Shionogi & Co., Ltd, Division of Molecular Pathobiology, Research Center for Zoonosis Control, Hokkaido University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33686154$$D View this record in MEDLINE/PubMed |
BookMark | eNp9ks1u1DAUhSNUREvpC7BAlth0E4h_YjsbpFFUSqUipBbYWo5zk3qUsQfbM2Levp6mhbaLemPLPufTudf3bXHgvIOieI-rT7ii8nNkuG5kWRFcSiYlKcWr4ohUrC4JJeTg0fmwOIlxWeVVk4bh5k1xSCmXHNfsqAjfr9oaGZimiMCN1gEE6FHyCP6uA8SIFu0ZQRHCFpCOSKOV72FCcRcTrNDgA0o3gHobjd9C2CE_IO2S3dqgMzLpMEKybkTXi6vrsvW_S_KueD3kNzi534-LX1_Pfrbfyssf5xft4rI0nNFUdlRXbBC6oZJ0vawo6SgFgQctTScorgWnTFZ93euha3qMa1NzwJprYLQxjB4XFzO393qp1sGudNgpr626u_BhVDokayZQpBMmE4ZBC846RiTFFKjAUkrasR5n1peZtd50K-gNuJTrewJ9-uLsjRr9VomGVZySDDi9BwT_ZwMxqVVuWW67duA3URHW5EIlrnmWfnwmXfpNcLlVe5UUDWdkn-jD40T_ojx8bRbIWWCCjzHAoIxNOlm_D2gnhSu1HyQ1D5LKg6TuBkmJbCXPrA_0F010NsUsdiOE_7FfcN0CksPZAg |
CitedBy_id | crossref_primary_10_3390_ijms222413202 crossref_primary_10_1126_scitranslmed_abq4064 crossref_primary_10_1016_j_ebiom_2023_104950 crossref_primary_10_1038_s41467_023_39341_4 crossref_primary_10_1016_j_isci_2023_106634 crossref_primary_10_1371_journal_pone_0307154 crossref_primary_10_1016_j_jinorgbio_2022_111805 crossref_primary_10_1038_s41598_024_83633_8 crossref_primary_10_3389_fmicb_2022_721103 crossref_primary_10_3390_biomedicines10092123 crossref_primary_10_1016_j_antiviral_2022_105342 crossref_primary_10_3390_biomedicines11061658 crossref_primary_10_1021_acs_jmedchem_2c01081 crossref_primary_10_1016_j_bbrc_2021_09_015 crossref_primary_10_4274_atfm_galenos_2024_68095 crossref_primary_10_7554_eLife_90316_3 crossref_primary_10_1007_s10787_025_01650_z crossref_primary_10_1021_acsomega_3c10484 crossref_primary_10_1007_s00018_024_05370_5 crossref_primary_10_1016_j_isci_2021_103120 crossref_primary_10_7554_eLife_90316 crossref_primary_10_3390_ijms222111739 |
Cites_doi | 10.1016/j.antiviral.2019.104541 10.1016/j.jim.2012.12.010 10.1038/s41564-020-0695-z 10.1128/JVI.01890-13 10.1074/jbc.RA120.013679 10.1128/JVI.79.15.9470-9479.2005 10.1021/acs.jmedchem.7b00734 10.1038/s41586-020-2012-7 10.1371/journal.ppat.1004166 10.1126/science.1110656 10.1038/d41573-020-00016-0 10.1016/S0140-6736(20)30251-8 10.1099/vir.0.81749-0 10.1128/JVI.79.6.3846-3850.2005 10.1073/pnas.2002589117 10.1038/s41586-020-2577-1 10.1056/NEJMoa030781 10.1038/s41422-020-0282-0 10.1073/pnas.1407087111 10.1038/nature02145 10.3390/biom9110696 10.1016/j.cell.2020.02.052 10.1038/s41423-020-0400-4 10.1038/s41467-020-15562-9 10.1016/j.celrep.2020.107940 10.1056/NEJMoa2007016 10.1073/pnas.2003138117 10.1016/S2666-5247(20)30004-5 10.1016/j.antiviral.2017.09.004 10.1099/jgv.0.001453 10.1128/JVI.00094-12 10.1073/pnas.1811345115 10.1016/j.antiviral.2020.104786 10.1101/2020.04.14.039925 10.7883/yoken.JJID.2005.88 |
ContentType | Journal Article |
Copyright | The Author(s) 2021 The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: The Author(s) 2021 – notice: The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU COVID DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
DOI | 10.1038/s41598-021-84882-7 |
DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College Coronavirus Research Database ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals - May need to register for free articles |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE Publicly Available Content Database CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: C6C name: Springer Nature Open Access Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 2045-2322 |
EndPage | 9 |
ExternalDocumentID | oai_doaj_org_article_2b7cd11ffa764b428313e3718883b4d1 PMC7940632 33686154 10_1038_s41598_021_84882_7 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Japan Agency for Medical Research and Development grantid: JP20wm0225003 funderid: http://dx.doi.org/10.13039/100009619 – fundername: Japan Agency for Medical Research and Development grantid: JP20wm0225003 – fundername: ; grantid: JP20wm0225003 |
GroupedDBID | 0R~ 3V. 4.4 53G 5VS 7X7 88A 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD ABDBF ABUWG ACGFS ACSMW ACUHS ADBBV ADRAZ AENEX AEUYN AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M0L M1P M2P M48 M7P M~E NAO OK1 PIMPY PQQKQ PROAC PSQYO RNT RNTTT RPM SNYQT UKHRP AASML AAYXX AFPKN CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 7XB 8FK AARCD COVID K9. PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS Q9U 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c643t-b3a04f7a9382bd8032b33e71fa8cb7315763480d5dafb9d115c56e1a6ae439c43 |
IEDL.DBID | 7X7 |
ISSN | 2045-2322 |
IngestDate | Tue Aug 26 23:45:37 EDT 2025 Thu Aug 21 13:51:10 EDT 2025 Fri Jul 11 00:51:05 EDT 2025 Wed Aug 13 07:16:35 EDT 2025 Thu Apr 03 06:56:41 EDT 2025 Tue Jul 01 01:07:38 EDT 2025 Thu Apr 24 23:01:43 EDT 2025 Fri Feb 21 02:39:16 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c643t-b3a04f7a9382bd8032b33e71fa8cb7315763480d5dafb9d115c56e1a6ae439c43 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://www.proquest.com/docview/2498796421?pq-origsite=%requestingapplication% |
PMID | 33686154 |
PQID | 2498796421 |
PQPubID | 2041939 |
PageCount | 9 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_2b7cd11ffa764b428313e3718883b4d1 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7940632 proquest_miscellaneous_2499388156 proquest_journals_2498796421 pubmed_primary_33686154 crossref_citationtrail_10_1038_s41598_021_84882_7 crossref_primary_10_1038_s41598_021_84882_7 springer_journals_10_1038_s41598_021_84882_7 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-03-08 |
PublicationDateYYYYMMDD | 2021-03-08 |
PublicationDate_xml | – month: 03 year: 2021 text: 2021-03-08 day: 08 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: England |
PublicationTitle | Scientific reports |
PublicationTitleAbbrev | Sci Rep |
PublicationTitleAlternate | Sci Rep |
PublicationYear | 2021 |
Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
References | Ou (CR17) 2020; 11 Zheng (CR14) 2018; 92 Chandran (CR28) 2005; 308 Lu (CR1) 2020; 395 Gorbalenya (CR2) 2020; 5 Hoffmann (CR11) 2020; 181 Brown (CR29) 2019; 169 CR34 Tai (CR15) 2020; 17 Riva (CR9) 2020 Ohnishi (CR38) 2005; 58 Goldhill (CR27) 2018; 115 Li (CR10) 2003; 426 Zhou (CR12) 2020; 579 Tseng (CR21) 2005; 79 Matsuyama (CR24) 2020; 117 Wang (CR25) 2020; 30 Corman (CR37) 2020; 25 Gordon (CR26) 2020; 295 Ogando (CR33) 2020 Mille, Whittaker (CR35) 2014; 111 Ksiazek (CR3) 2003; 348 Mehellou, Rattan, Balzarini (CR31) 2018; 61 Mossel (CR7) 2005; 79 Shang (CR16) 2020; 117 Kawase, Shirato, van der Hoek, Taguchi, Matsuyama (CR13) 2012; 86 Ren (CR22) 2006; 87 Chu (CR6) 2020; 1 Wang (CR18) 2012; 20 Choy (CR32) 2020; 178 Shirato, Kawase, Matsuyama (CR20) 2013; 87 Mumtaz (CR30) 2017; 146 Kim (CR36) 2019; 9 Liao, Sikkema, Wang, Lee (CR23) 2013; 389 Li, De Clercq (CR4) 2020; 19 Pruijssers (CR8) 2020; 32 Lundin (CR19) 2014; 10 Grein (CR5) 2020; 382 K Chandran (84882_CR28) 2005; 308 R Lu (84882_CR1) 2020; 395 K Ohnishi (84882_CR38) 2005; 58 C-TK Tseng (84882_CR21) 2005; 79 AE Gorbalenya (84882_CR2) 2020; 5 AJ Brown (84882_CR29) 2019; 169 JK Mille (84882_CR35) 2014; 111 AJ Pruijssers (84882_CR8) 2020; 32 W Li (84882_CR10) 2003; 426 CJ Gordon (84882_CR26) 2020; 295 Kim (84882_CR36) 2019; 9 Y Mehellou (84882_CR31) 2018; 61 M Hoffmann (84882_CR11) 2020; 181 M Wang (84882_CR25) 2020; 30 J Grein (84882_CR5) 2020; 382 K Shirato (84882_CR20) 2013; 87 S Matsuyama (84882_CR24) 2020; 117 H Chu (84882_CR6) 2020; 1 L Riva (84882_CR9) 2020 K Liao (84882_CR23) 2013; 389 M Kawase (84882_CR13) 2012; 86 N Mumtaz (84882_CR30) 2017; 146 G Li (84882_CR4) 2020; 19 P Zhou (84882_CR12) 2020; 579 J Shang (84882_CR16) 2020; 117 A Lundin (84882_CR19) 2014; 10 Y Zheng (84882_CR14) 2018; 92 DY Wang (84882_CR18) 2012; 20 X Ren (84882_CR22) 2006; 87 DH Goldhill (84882_CR27) 2018; 115 NS Ogando (84882_CR33) 2020 W Tai (84882_CR15) 2020; 17 VM Corman (84882_CR37) 2020; 25 KT Choy (84882_CR32) 2020; 178 EC Mossel (84882_CR7) 2005; 79 84882_CR34 X Ou (84882_CR17) 2020; 11 TG Ksiazek (84882_CR3) 2003; 348 |
References_xml | – volume: 169 start-page: 104541 year: 2019 ident: CR29 article-title: Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase publication-title: Antiviral Res. doi: 10.1016/j.antiviral.2019.104541 – volume: 389 start-page: 52 year: 2013 end-page: 60 ident: CR23 article-title: Development of an enzymatic assay for the detection of neutralizing antibodies against therapeutic angiotensin-converting enzyme 2 (ACE2) publication-title: J. Immunol. Methods doi: 10.1016/j.jim.2012.12.010 – volume: 5 start-page: 536 year: 2020 end-page: 544 ident: CR2 article-title: The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 publication-title: Nat. Microbiol. doi: 10.1038/s41564-020-0695-z – volume: 87 start-page: 12552 year: 2013 end-page: 12561 ident: CR20 article-title: Middle east respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2 publication-title: J. Virol. doi: 10.1128/JVI.01890-13 – volume: 295 start-page: 6785 year: 2020 end-page: 6797 ident: CR26 article-title: Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency publication-title: J. Biol. Chem. doi: 10.1074/jbc.RA120.013679 – volume: 79 start-page: 9470 year: 2005 end-page: 9479 ident: CR21 article-title: Apical entry and release of severe acute respiratory syndrome-associated coronavirus in polarized calu-3 lung epithelial cells publication-title: J. Virol. doi: 10.1128/JVI.79.15.9470-9479.2005 – volume: 61 start-page: 2211 year: 2018 end-page: 2226 ident: CR31 article-title: The protide prodrug technology: from the concept to the clinic publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.7b00734 – volume: 579 start-page: 270 year: 2020 end-page: 273 ident: CR12 article-title: A pneumonia outbreak associated with a new coronavirus of probable bat origin publication-title: Nature doi: 10.1038/s41586-020-2012-7 – volume: 10 start-page: e1004166 year: 2014 ident: CR19 article-title: Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the middle east respiratory syndrome virus publication-title: PLoS Pathog. doi: 10.1371/journal.ppat.1004166 – volume: 308 start-page: 1643 year: 2005 end-page: 1645 ident: CR28 article-title: Endosomal proteolysis of the ebola virus glycoprotein is necessary for infection publication-title: Science doi: 10.1126/science.1110656 – volume: 19 start-page: 149 year: 2020 end-page: 150 ident: CR4 article-title: Therapeutic options for the 2019 novel coronavirus (2019-nCoV) publication-title: Nat. Rev. Drug Discov. doi: 10.1038/d41573-020-00016-0 – volume: 395 start-page: 565 year: 2020 end-page: 574 ident: CR1 article-title: Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding publication-title: Lancet doi: 10.1016/S0140-6736(20)30251-8 – volume: 87 start-page: 1691 year: 2006 end-page: 1695 ident: CR22 article-title: Analysis of ACE2 in polarized epithelial cells: Surface expression and function as receptor for severe acute respiratory syndrome-associated coronavirus publication-title: J. Gen. Virol. doi: 10.1099/vir.0.81749-0 – volume: 79 start-page: 3846 year: 2005 end-page: 3850 ident: CR7 article-title: Exogenous ACE2 expression allows refractory cell lines to support severe acute respiratory syndrome coronavirus replication publication-title: J. Virol. doi: 10.1128/JVI.79.6.3846-3850.2005 – volume: 92 start-page: 1 year: 2018 end-page: 14 ident: CR14 article-title: Lysosomal proteases are a determinant of coronavirus tropism publication-title: J. Virol. – volume: 117 start-page: 7001 year: 2020 end-page: 7003 ident: CR24 article-title: Enhanced isolation of SARS-CoV-2 by TMPRSS2- expressing cells publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.2002589117 – year: 2020 ident: CR9 article-title: Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing publication-title: Nature doi: 10.1038/s41586-020-2577-1 – volume: 20 start-page: 938 year: 2012 end-page: 946 ident: CR18 article-title: Establishment of a serological panel for in vitro diagnostics of severe acute respiratory syndrome publication-title: J. Food Drug Anal. – volume: 58 start-page: 88 year: 2005 end-page: 94 ident: CR38 article-title: Immunological detection of severe acute respiratory syndrome coronavirus by monoclonal antibodies publication-title: Jpn. J. Infect. Dis. – volume: 348 start-page: 1953 year: 2003 end-page: 1966 ident: CR3 article-title: A novel coronavirus associated with severe acute respiratory syndrome publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa030781 – volume: 30 start-page: 269 year: 2020 end-page: 271 ident: CR25 article-title: Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro publication-title: Cell Res. doi: 10.1038/s41422-020-0282-0 – volume: 111 start-page: 15214 year: 2014 end-page: 15219 ident: CR35 article-title: Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.1407087111 – volume: 25 start-page: 1 year: 2020 end-page: 8 ident: CR37 article-title: Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR publication-title: Eurosurveillance – volume: 426 start-page: 450 year: 2003 end-page: 454 ident: CR10 article-title: Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus publication-title: Nature doi: 10.1038/nature02145 – volume: 9 start-page: 696 year: 2019 ident: CR36 article-title: Natural bis-benzylisoquinoline alkaloids-tetrandrine, fangchinoline, and cepharanthine, inhibit human coronavirus OC43 Infection of MRC-5 human lung cells publication-title: Biomolecules doi: 10.3390/biom9110696 – volume: 181 start-page: 271 year: 2020 end-page: 280.e8 ident: CR11 article-title: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor publication-title: Cell doi: 10.1016/j.cell.2020.02.052 – volume: 17 start-page: 613 year: 2020 end-page: 620 ident: CR15 article-title: Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine publication-title: Cell. Mol. Immunol. doi: 10.1038/s41423-020-0400-4 – volume: 11 start-page: 1620 year: 2020 ident: CR17 article-title: Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV publication-title: Nat. Commun. doi: 10.1038/s41467-020-15562-9 – volume: 32 start-page: 107940 year: 2020 ident: CR8 article-title: Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice publication-title: Cell Rep. doi: 10.1016/j.celrep.2020.107940 – volume: 382 start-page: 2327 year: 2020 end-page: 2336 ident: CR5 article-title: Compassionate use of remdesivir for patients with severe Covid-19 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2007016 – volume: 117 start-page: 11727 year: 2020 end-page: 11734 ident: CR16 article-title: Cell entry mechanisms of SARS-CoV-2 publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.2003138117 – ident: CR34 – volume: 1 start-page: e14 year: 2020 end-page: e23 ident: CR6 article-title: Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study publication-title: The Lancet Microbe doi: 10.1016/S2666-5247(20)30004-5 – volume: 146 start-page: 161 year: 2017 end-page: 163 ident: CR30 article-title: Cell-line dependent antiviral activity of sofosbuvir against Zika virus publication-title: Antiviral Res. doi: 10.1016/j.antiviral.2017.09.004 – year: 2020 ident: CR33 article-title: SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology publication-title: J. Gen. Virol. doi: 10.1099/jgv.0.001453 – volume: 86 start-page: 6537 year: 2012 end-page: 6545 ident: CR13 article-title: Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry publication-title: J. Virol. doi: 10.1128/JVI.00094-12 – volume: 115 start-page: 11613 year: 2018 end-page: 11618 ident: CR27 article-title: The mechanism of resistance to favipiravir in influenza publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.1811345115 – volume: 178 start-page: 104786 year: 2020 ident: CR32 article-title: Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro publication-title: Antiviral Res. doi: 10.1016/j.antiviral.2020.104786 – volume: 87 start-page: 1691 year: 2006 ident: 84882_CR22 publication-title: J. Gen. Virol. doi: 10.1099/vir.0.81749-0 – volume: 395 start-page: 565 year: 2020 ident: 84882_CR1 publication-title: Lancet doi: 10.1016/S0140-6736(20)30251-8 – volume: 11 start-page: 1620 year: 2020 ident: 84882_CR17 publication-title: Nat. Commun. doi: 10.1038/s41467-020-15562-9 – volume: 25 start-page: 1 year: 2020 ident: 84882_CR37 publication-title: Eurosurveillance – volume: 9 start-page: 696 year: 2019 ident: 84882_CR36 publication-title: Biomolecules doi: 10.3390/biom9110696 – volume: 17 start-page: 613 year: 2020 ident: 84882_CR15 publication-title: Cell. Mol. Immunol. doi: 10.1038/s41423-020-0400-4 – volume: 426 start-page: 450 year: 2003 ident: 84882_CR10 publication-title: Nature doi: 10.1038/nature02145 – volume: 308 start-page: 1643 year: 2005 ident: 84882_CR28 publication-title: Science doi: 10.1126/science.1110656 – volume: 87 start-page: 12552 year: 2013 ident: 84882_CR20 publication-title: J. Virol. doi: 10.1128/JVI.01890-13 – year: 2020 ident: 84882_CR33 publication-title: J. Gen. Virol. doi: 10.1099/jgv.0.001453 – volume: 117 start-page: 7001 year: 2020 ident: 84882_CR24 publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.2002589117 – volume: 115 start-page: 11613 year: 2018 ident: 84882_CR27 publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.1811345115 – volume: 111 start-page: 15214 year: 2014 ident: 84882_CR35 publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.1407087111 – volume: 79 start-page: 9470 year: 2005 ident: 84882_CR21 publication-title: J. Virol. doi: 10.1128/JVI.79.15.9470-9479.2005 – volume: 382 start-page: 2327 year: 2020 ident: 84882_CR5 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2007016 – volume: 20 start-page: 938 year: 2012 ident: 84882_CR18 publication-title: J. Food Drug Anal. – volume: 295 start-page: 6785 year: 2020 ident: 84882_CR26 publication-title: J. Biol. Chem. doi: 10.1074/jbc.RA120.013679 – volume: 92 start-page: 1 year: 2018 ident: 84882_CR14 publication-title: J. Virol. – volume: 389 start-page: 52 year: 2013 ident: 84882_CR23 publication-title: J. Immunol. Methods doi: 10.1016/j.jim.2012.12.010 – volume: 79 start-page: 3846 year: 2005 ident: 84882_CR7 publication-title: J. Virol. doi: 10.1128/JVI.79.6.3846-3850.2005 – volume: 10 start-page: e1004166 year: 2014 ident: 84882_CR19 publication-title: PLoS Pathog. doi: 10.1371/journal.ppat.1004166 – volume: 86 start-page: 6537 year: 2012 ident: 84882_CR13 publication-title: J. Virol. doi: 10.1128/JVI.00094-12 – volume: 32 start-page: 107940 year: 2020 ident: 84882_CR8 publication-title: Cell Rep. doi: 10.1016/j.celrep.2020.107940 – volume: 19 start-page: 149 year: 2020 ident: 84882_CR4 publication-title: Nat. Rev. Drug Discov. doi: 10.1038/d41573-020-00016-0 – ident: 84882_CR34 doi: 10.1101/2020.04.14.039925 – volume: 348 start-page: 1953 year: 2003 ident: 84882_CR3 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa030781 – volume: 178 start-page: 104786 year: 2020 ident: 84882_CR32 publication-title: Antiviral Res. doi: 10.1016/j.antiviral.2020.104786 – volume: 5 start-page: 536 year: 2020 ident: 84882_CR2 publication-title: Nat. Microbiol. doi: 10.1038/s41564-020-0695-z – year: 2020 ident: 84882_CR9 publication-title: Nature doi: 10.1038/s41586-020-2577-1 – volume: 1 start-page: e14 year: 2020 ident: 84882_CR6 publication-title: The Lancet Microbe doi: 10.1016/S2666-5247(20)30004-5 – volume: 61 start-page: 2211 year: 2018 ident: 84882_CR31 publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.7b00734 – volume: 58 start-page: 88 year: 2005 ident: 84882_CR38 publication-title: Jpn. J. Infect. Dis. doi: 10.7883/yoken.JJID.2005.88 – volume: 30 start-page: 269 year: 2020 ident: 84882_CR25 publication-title: Cell Res. doi: 10.1038/s41422-020-0282-0 – volume: 146 start-page: 161 year: 2017 ident: 84882_CR30 publication-title: Antiviral Res. doi: 10.1016/j.antiviral.2017.09.004 – volume: 181 start-page: 271 year: 2020 ident: 84882_CR11 publication-title: Cell doi: 10.1016/j.cell.2020.02.052 – volume: 117 start-page: 11727 year: 2020 ident: 84882_CR16 publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.2003138117 – volume: 579 start-page: 270 year: 2020 ident: 84882_CR12 publication-title: Nature doi: 10.1038/s41586-020-2012-7 – volume: 169 start-page: 104541 year: 2019 ident: 84882_CR29 publication-title: Antiviral Res. doi: 10.1016/j.antiviral.2019.104541 |
SSID | ssj0000529419 |
Score | 2.4381807 |
Snippet | Although the spread of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has resulted in a worldwide pandemic, there are currently no virus-specific... Abstract Although the spread of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has resulted in a worldwide pandemic, there are currently no... |
SourceID | doaj pubmedcentral proquest pubmed crossref springer |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 5376 |
SubjectTerms | 631/326 631/326/596 631/326/596/1296 631/326/596/4130 ACE2 Angiotensin Angiotensin-converting enzyme 2 Angiotensin-Converting Enzyme 2 - metabolism Animals Antiviral agents Antiviral Agents - pharmacology Antiviral Agents - therapeutic use Antiviral drugs Cell Engineering Cell Line Coronaviruses COVID-19 COVID-19 - drug therapy Drug development Drug Discovery Humanities and Social Sciences Humans Infectivity Models, Biological multidisciplinary Pandemics Peptidyl-dipeptidase A Replication Ribonucleic acid RNA RNA viruses SARS-CoV-2 - drug effects SARS-CoV-2 - physiology Science Science (multidisciplinary) Severe acute respiratory syndrome coronavirus 2 Vaccine development Vero cells Viral Proteins - biosynthesis Virus Replication - drug effects |
SummonAdditionalLinks | – databaseName: Directory of Open Access Journals - May need to register for free articles dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlUOilNH26SYsKvbUi1sOWfNwuCaGQHpKm5CYkWaKBYpfsBpJ_nxnJu8mmr0uvlmyGeVifpJlvCHlv2iYEgLosgAcx5Y1nToeGYSfGOgmhdS4SO_rSHp6qz2fN2Z1WX5gTVuiBi-L2hNeh5zwlp1vlkR4Mz-3gj2qM9KrPGx9Y8-5spgqrt-gU76YqmVqavQWsVFhNJjgzKsPKjZUoE_b_DmX-mix578Y0L0QHT8jjCUHSWZF8mzyIw1PysPSUvH5GLo6O5w3F8_gFjRPZYOzpcqTxKie90tl8X1A8jI3ULaijuRkOLZTOFDAsBUxIsVoXszuv6ZgoaP8ck4HhkyVzHASjJ7PjEzYfvzHxnJwe7H-dH7KpsQILAECWzEtXq6RdJ43wvaml8FJGzZMzwWvJYQ8ilan7pnfJd6D9JjRt5K51EfBLUPIF2RrGIb4iNHVedSpGg7z2ifemCamNfS1QYVJ2FeErJdswsY5j84sfNt9-S2OLYSwYxmbDWF2RD-t3fhbOjb_O_oS2W89Evuz8ALzITl5k_-VFFdldWd5OQbywsDM1WKkrYPjdehjCD23ohjhe5jmgRaTcqcjL4ihrSaRsDQBGVRG94UIbom6ODOffM8U3_CUBO4qKfFw5261Yf1bF6_-hih3ySGCUYJ6d2SVby4vL-AaA19K_zTF2A_a0JdI priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fb9MwELbGEBIviN8EBjISb2BIbCd2HhAq1aYJqTxsFO3Nsh17TJoSaDtp_e-5c5KiQtlrbEfO3Tn32b77jpA3uiq9B6jLPFgQk047ZpUvGVZizCPnSqUksdnX6nguv5yVZ3tkLHc0CHC5c2uH9aTmi8v317_Wn2DBf-xTxvWHJTghTBTjBdMyIcZb5DZ4JoUVDWYD3O-5vnkti3rIndk9dMs_JRr_Xdjz3xDKv-5Rk3s6uk_uDbiSTnpDeED2QvuQ3OkrTa4fkcXsZFpSPKVf0jBQEIaGrjoarlMoLJ1MDznFI9pA7ZJamkrk0J7omQKypYAUKebwYsznmnaRgk4uMEQYXtnHk8PE6Onk5JRNu--MPybzo8Nv02M2lFtgHmDJijlhcxmVrYXmrtG54E6IoIpotXdKFLAzEVLnTdnY6OoGoKQvq1DYygZANV6KJ2S_7drwjNBYO1nLEDSy3cei0aWPVWhyjgITos5IMQrZ-IGLHEtiXJp0Jy606RVjQDEmKcaojLzdjPnZM3Hc2Psz6m7TE1m004NucW6GRWm4Ux6-I0arKumQeg7PhMFbay2cbIqMHIyaN6NlGtivaszf5dD8etMMixJ1aNvQXaU-IEUk4snI095QNjMRotIAI2VG1JYJbU11u6W9-JGIv-HfCYiSZ-TdaGx_pvV_UTy_-StekLsc7R_j6vQB2V8trsJLAFor9yqtnt_BcSFH priority: 102 providerName: Scholars Portal – databaseName: Springer Nature HAS Fully OA dbid: AAJSJ link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZKKyQuiDeBgozEDSwS24mdY1i1qlYqhy5FvVm2Y0OlKkG7W4n-e2acB1ooSFxjO5rMjO0v9sw3hLzVVek9QF3mwYOYdNoxq3zJsBJjHjlXKiWJnX6qTs7l8qK82CN8yoVJQfuJ0jIt01N02IcNbDSYDMYLpmVChXfIAVK1g28fNM1ytZxPVvDuShb1mCGTC33L4J1dKJH134Yw_wyU_O22NG1Cxw_I_RE90maQ9yHZC90jcneoJ3nzmKxPzxYlxbP4DQ0j0WBo6ban4UcKeKXN4ohTPIgN1G6opakQDh3onCngVwp4kGKmLkZ23tA-UtD8JQYCwyuHqHEQjK6asxVb9F8Yf0LOj48-L07YWFSBeQAfW-aEzWVUthaau1bngjshgiqi1d4pUcD_h5A6b8vWRle3ABh9WYXCVjYAdvFSPCX7Xd-F54TG2slahqCR0z4WrS59rEKbc1SYEHVGiknJxo-M41j44sqkm2-hzWAYA4YxyTBGZeTdPOb7wLfxz94f0XZzT-TKTg_69Vcz-o7hTnn4jhitqqRDgjk8-YU9WWvhZFtk5HCyvBkn8MbAX6nGLF0OzW_mZph6aEPbhf469QEtIt1ORp4NjjJLIkSlASzKjKgdF9oRdbelu_yW6L1hhQTcyDPyfnK2X2L9XRUv_q_7S3KP43zAaDp9SPa36-vwCuDV1r0e59NPfocdRQ priority: 102 providerName: Springer Nature |
Title | MRC5 cells engineered to express ACE2 serve as a model system for the discovery of antivirals targeting SARS-CoV-2 |
URI | https://link.springer.com/article/10.1038/s41598-021-84882-7 https://www.ncbi.nlm.nih.gov/pubmed/33686154 https://www.proquest.com/docview/2498796421 https://www.proquest.com/docview/2499388156 https://pubmed.ncbi.nlm.nih.gov/PMC7940632 https://doaj.org/article/2b7cd11ffa764b428313e3718883b4d1 |
Volume | 11 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swEBdby2AvY9_z1gUN9raJ2pJsyU_DNSklkDKSdeTNSLK8FYbdxSms__3uZCcl--iLDZJsZN1J-vl09ztC3ussdQ6gLnOgQUxabZlRLmWYiTFuOFcqBInNz7OzCzlbpavR4NaPbpXbNTEs1HXn0EZ-DL8JGsMmefLp6ifDrFF4ujqm0LhPDpG6DLVardTOxoKnWDLJx1iZWOjjHvYrjCnjCdMygMu9_SjQ9v8La_7tMvnHuWnYjk4fk0cjjqTFIPgn5J5vn5IHQ2bJm2dkPV-UKUWrfE_9SDnoa7rpqP8VXF9pUU45RZOsp6anhoaUOHQgdqaAZCkgQ4oxu-jjeUO7hoIMLtElGF45-I9Dx-iyWCxZ2X1l_Dm5OJ1-Kc_YmF6BOYAhG2aFiWWjTC40t7WOBbdCeJU0RjurRAJ_IkLquE5r09i8Bujo0swnJjMeUIyT4gU5aLvWvyK0ya3Mpfca2e2bpNapazJfxxwHTIg8Isl2kCs3co9jCowfVTgDF7oaBFOBYKogmEpF5MPumauBeePO1icou11LZM0OBd36WzVOwopb5eA7msaoTFqkmkMbMOzOWgsr6yQiR1vJV-NU7qtbxYvIu101TEKUoWl9dx3awCgi8U5EXg6KsuuJEJkG2CgjovZUaK-r-zXt5fdA9A1rJSBIHpGPW2W77db_h-L13V_xhjzkqP_oR6ePyMFmfe3fArDa2EmYPRNyWBSz5QzuJ9PzzwsoLbNyEowVcJ1L_RsO3iPq |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Jb9QwFLZKEYILYidQwEhwAquJ7cTOAaFhaDWlnR66oLm5seNAJZSUmalg_hS_kfecZKph6a3X2Imct_h99tsIeaWz1DmAusyBBDFptWWFcinDToxxxblSIUlsvJ-NjuWnSTpZI7_6XBgMq-z3xLBRl43DO_JNOCZoTJvkyfuz7wy7RqF3tW-h0YrFrl_8gCPb7N3OR-Dva863t46GI9Z1FWAOrO-cWVHEslJFLjS3pY4Ft0J4lVSFdlaJBAC4kDou07KobF4CYnJp5pMiKzwYbycFfPcauQ6GN8bDnpqo5Z0Oes1kkne5ObHQmzOwj5jDxhOmZQCzK_YvtAn4F7b9O0TzDz9tMH_bd8jtDrfSQStod8mar--RG20ny8V9Mh0fDFOKXoAZ9V2JQ1_SeUP9zxBqSwfDLU7xCtjTYkYLGlrw0LaQNAXkTAGJUswRxpjSBW0qCjw_xRBk-GQbrw4Lo4eDg0M2bD4z_oAcXwnhH5L1uqn9Y0Kr3Mpceq-xmn6VlDp1VebLmCPBhMgjkvRENq6rdY4tN76Z4HMX2rSMMcAYExhjVETeLN85ayt9XDr7A_JuOROrdIcHzfSL6ZTecKsc_EdVFSqTFkvb4Z0zoAGthZVlEpGNnvOm2zpm5kLQI_JyOQxKjzwsat-chzlARSz0E5FHraAsVyJEpgGmyoioFRFaWerqSH36NRQWh70ZECuPyNte2C6W9X9SPLn8L16Qm6Oj8Z7Z29nffUpucdQFjOHTG2R9Pj33zwDUze3zoEmUnFy16v4GSJ1anw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NTiBeEN8EBhgJniBqYjuJ84BQ17XaGKumjqG9hdhxYBJKRtsJ-q_x13HnJJ3Kx972GjuRc3e--9n3BfBSxZExCHV9gxLkS620nycm8qkTY1ByniQuSexgEu8ey_cn0ckG_OpyYSisstOJTlEXtaE78j4eExSlTfKwX7ZhEYc743dn333qIEWe1q6dRiMi-3b5A49v87d7O8jrV5yPRx-Hu37bYcA3aIkXvhZ5IMskT4XiulCB4FoIm4RlroxORIhgXEgVFFGRlzotED2ZKLZhHucWDbmRAr97DTYTOhX1YHN7NDmcrm54yIcmw7TN1AmE6s_RWlJGGw99JR20XbOGrmnAv5Du3wGbf3htnTEc34ZbLYplg0bs7sCGre7C9aav5fIezA6mw4iRT2DObFvw0BZsUTP70wXessFwxBldCFuWz1nOXEMe1pSVZoijGeJSRhnDFGG6ZHXJUAJOKSAZP9lEr-PC2NFgeuQP608-vw_HV0L6B9Cr6so-AlamWqbSWkW19cuwUJEpY1sEnAgmROpB2BE5M23lc2rA8S1zHnihsoYxGTImc4zJEg9er945a-p-XDp7m3i3mkk1u92DevYla1VAxnVi8D_KMk9iqanQHd1AIzZQSmhZhB5sdZzPWkUyzy7E3oMXq2FUAcTDvLL1uZuDVKSyPx48bARltRIhYoWgVXqQrInQ2lLXR6rTr67MOGpqxK_cgzedsF0s6_-keHz5XzyHG7htsw97k_0ncJPTVqCAPrUFvcXs3D5FhLfQz9qtxODzVe_e35MAYDo |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MRC5+cells+engineered+to+express+ACE2+serve+as+a+model+system+for+the+discovery+of+antivirals+targeting+SARS-CoV-2&rft.jtitle=Scientific+reports&rft.au=Uemura+Kentaro&rft.au=Sasaki+Michihito&rft.au=Sanaki+Takao&rft.au=Toba+Shinsuke&rft.date=2021-03-08&rft.pub=Nature+Publishing+Group&rft.eissn=2045-2322&rft.volume=11&rft.issue=1&rft_id=info:doi/10.1038%2Fs41598-021-84882-7&rft.externalDBID=HAS_PDF_LINK |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |